Clinical trial
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung…
NCT00452413 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00452413 |
|---|---|
| Title | A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer |
| Official title | A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer, Malignant Solid Tumor |
| Intervention type | Drug |
| Interventions | enzastaurin, erlotinib |
| Enrollment | 65 |
| Start date | May 1, 2007 |
| Primary completion | Jul 1, 2009 |
| Completion | Nov 1, 2013 |
| First posted | Mar 27, 2007 |
| Last update posted | May 13, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: